No immediate trading implications. Monitor the annual meeting on June 17, 2026 for any unexpected proxy contest or changes to board composition.
MDGL drugs
MDGL drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 29 $518.58entry
- T+1 · 7mo ago −0.23%α −1.25% · $517.39
- T+5 · 7mo ago +4.08%α +0.97% · $539.73
- T+20 · 6mo ago −0.51%α −6.55% · $515.96
- T+60 · 4mo ago +5.00%α +0.89% · $544.51
Price Chart
How similar events traded
Executive Summary
Madrigal Pharmaceuticals reclassified two directors (Julian Baker and Daniel Brennan) to Class I to balance board classes ahead of the June 17, 2026 annual meeting. This is a routine administrative change with no material impact on operations or strategy.
Key Facts
- Julian C. Baker and Daniel J. Brennan reclassified as Class I directors effective April 22, 2026.
- Reclassification balances board classes; no change in committee assignments.
- Both directors, along with James Daly, are nominated for re-election at the June 17, 2026 annual meeting.
Financial Impact
No financial impact from this board reorganization.
Risk Factors
- Risk of contested director elections if shareholders oppose nominees, though currently no indication of opposition.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-027956 |
| Document: 0001628280-26-027956-index-headers.html | 0001628280-26-027956 |
| Document: 0001628280-26-027956-index.html | 0001628280-26-027956 |
| Document: 0001628280-26-027956.txt | 0001628280-26-027956 |
Track record
18 reports on MDGL
3 of 6 bullish or bearish reports moved the stock their way by T+5. Best: +10.26% at T+20 after the Jul 30, 2026 report. 3 of 6 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $424.08 Now $423.96 −0.03% settles Nov 23
- Nov 6, 202610d ago SC 13D/A Neutral 3/10 Entry $432.79 to $423.96 Now $423.96 −2.04% ▼ −2.04% −0.35% vs SPY
- Nov 6, 202610d ago Insider Buy Bullish 5/10 Entry $432.79 to $423.96 Now $423.96 −2.04% ▼ −2.04% −0.35% vs SPY
- Nov 6, 202610d ago Insider Cluster Bullish 5/10 Entry $432.79 to $423.96 Now $423.96 −2.04% ▼ −2.04% −0.35% vs SPY
- Nov 6, 202610d ago 144 Neutral 2/10 Entry $432.79 to $423.96 Now $423.96 −2.04% ▼ −2.04% −0.35% vs SPY
- Nov 5, 202611d ago Institutional Cluster Mixed 3/10 Entry $400.10 to $425.21 Now $423.96 +5.96% ▲ +6.28% +2.99% vs SPY
- Nov 5, 202611d ago Press Release Bullish 5/10 Entry $400.10 to $425.21 Now $423.96 +5.96% ▲ +6.28% +2.99% vs SPY
- Nov 3, 202613d ago 8-K Bullish 7/10 No price data
- Nov 3, 202613d ago Press Release Bullish 6/10 Entry $396.32 to $432.60 Now $423.96 +6.97% ▲ +9.15% +9.74% vs SPY
- Aug 12, 202613w ago 8-K Neutral 3/10 Entry $536.20 to $540.16 Now $423.96 −20.93% ▲ +0.74% +1.18% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers